Qiagen's shares rose 8 percent for the five-day trading period ended Tuesday, leading the 13 firms that posted gains in the BCW Index. Qiagen reported a 9-percent increase in fourth-quarter revenues on Monday after the close of the market. Its shares gained 5.4 percent in the first full day of trading after the results were released. Only three firms posted declines in their stock for the tracking period, led by Invitrogen, which fell 1.3 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.